Drugs / Lumretuzumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01918254 | Aug 2013 → Oct 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01482377 | Dec 2011 → Feb 2016 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02204345 | Oct 2014 → Mar 2016 | non-small cell squamous lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lumretuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01918254 ↗ |
| Known as | RG-7116 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707404 ↗ |
| Known as | RO5479599 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482377 ↗ |
| Action | Inhibit | “receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2)” PMID 29349598 ↗ Jan 20181“Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3707404 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3707404 ↗ |
| Route | Intravenous | “Cohorts of participants will receive escalating doses of intravenous RO5479599” NCT01482377 ↗ |
| Target | ERBB3 | “Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3707404 ↗ |